Tyrosine-protein kinase Fes/Fps (also known as proto-oncogene c-Fes/Fps) and together with the homologous kinase Fer, defines a structurally unique kinase family. c-Fes is present in a variety of cell lineages, including myeloid hematopoietic, vascular endothelial, neuronal and epithelial cells. Active c-Fes has been observed in acute myeloid leukemia (AML), and reduction of c-fes expression by RNAi demonstrated a requirement for c-Fes in AML cell survival.
Selective small molecule inhibitors are urgently needed to clarify the roles of c-Fes as dominant oncogene vs. tumor suppressor depending upon the cellular context. Despite the intriguing biology associated with c-Fes, very limited inhibitors with a useful level of selectivity and cellular activity have been reported to date.
TAE684, a compound previously identified as a potent and selective inhibitor of the anaplastic lymphoma kinase (ALK), is also a potent inhibitor of c-Fes both in vitro and in vivo. WZ-4-49-8 as well as HG-7-92-01 demonstrated strong inhibition of c-Fes in vitro. WZ-4-49-8 potently inhibited c-Fes-L145P-mediated soft-agar colony growth and showed remarkable selectivity for c-Fes-L145P over several active SFKs tested.
1. Hellwig S, et al. Chem Biol. 2012 Apr 20;19(4):529-40.
2. Fei F, et al. BMC Biochem. 2010 Dec 1;11:48.
3. Olvedy M, et al. J Clin Invest. 2017 Jun 1;127(6):2310-2325.
4. Kanda S, et al. J Biol Chem. 2003 Mar 7;278(10):8244-9.
5. Stanicka J, et al. Oncogene. 2018 Jun;37(23):3131-3150.